Topical immunosuppressants for blepharitis in adults
Authors:
- Ka Wai KamaKKKa Wai Kama
- Alvin L. YoungAYAlvin L. Young
- Supported By The Cochrane EyesSESupported By The Cochrane Eyes
- 20 November 2025
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (11) , CD013550
Abstract
Rationale Blepharitis is a common ocular condition characterized by inflammation of the eyelid margins, which can cause irritating symptoms and ocular surface damage. Conventional treatment of blepharitis consists of eyelid hygiene and artificial tears. To suppress inflammation, topical corticosteroids, with or without antibiotics, are frequently prescribed. However, long‐term use is limited by side effects such as increased intraocular pressure, glaucoma and/or cataract formation. Newer steroid‐sparing topical immunosuppressants have emerged as alternative treatments. Objectives To assess the benefits and harms of topical immunosuppressants for blepharitis in adults. Search methods We searched CENTRAL, MEDLINE, Embase, and three trial registries from inception to 6 April 2025. We searched the reference lists of included studies for any additional studies not identified by the electronic searches. There were no date or language restrictions on the selection of eligible studies. Eligibility criteria We included randomized controlled trials (RCTs) comparing topical immunosuppressants (corticosteroids, cyclosporine, or tacrolimus) of different doses or carrier, with placebo, no treatment, conventional treatment (lid hygiene, artificial tears) or other topical immunosuppressants in adults with blepharitis. We excluded paired‐eye studies and highly specific blepharitis subtypes. Outcomes Our outcomes were: (1) change from baseline in composite (or total) symptom score; (2) change from baseline in tear film breakup time; (3) change from baseline in corneal staining scores; (4) proportion of individuals experiencing symptomatic improvement; (5) reduction in number of or eradication of colonies of positive cultures of bacteria; (6) quality of life measures; (7) economic costs of different topical immunosuppressants; and (8) adverse effects. Risk of bias We used Cochrane's risk of bias (RoB) 2 tool for all outcomes reported in the summary of findings tables. Synthesis methods Two review authors independently selected trials, extracted data, and assessed risk of bias. We used fixed‐effect meta‐analysis to combine data and forest plots to assess heterogeneity, effect size, and direction. We used GRADE to assess the certainty of evidence for each outcome. When meta‐analysis was not possible, we used narrative synthesis. Included studies We included 12 RCTs with 2752 participants (2802 eyes) in total. Six of the trials were conducted in the USA. Topical corticosteroid was the most frequently studied immunosuppressant, followed by cyclosporine and tacrolimus. The point of assessment and duration of treatment ranged from two to 12 weeks. No study measured the proportion of individuals experiencing symptomatic improvement. Synthesis of results We report outcomes of interest for three key comparisons below at four to 12 weeks. No study assessed reduction or eradication of colonies of positive cultures of bacteria, quality of life or economic costs. Topical corticosteroids (with or without antibiotics) versus placebo The evidence is very uncertain about the effects of topical corticosteroids on composite symptom scores (corticosteroids with antibiotics: standard mean difference [SMD] 0.87, 95% confidence interval [CI] 0.31 to 1.44; 2 studies, 57 participants; corticosteroids alone: SMD ‐0.05, 95% CI ‐0.31 to 0.20; 2 studies, 232 participants; very low‐certainty evidence). No study reported tear breakup time. The evidence is very uncertain about the effects of topical corticosteroids on corneal staining scores (corticosteroids with antibiotics: MD 0.70, 95% CI ‐1.05 to 2.45; 1 study, 27 participants; corticosteroids alone: MD 0.50, 95% CI ‐1.22 to 2.22; 1 study, 27 participants); both, very low‐certainty evidence. The adverse event of irritation of the ocular surface was reported narratively and was similar between the two groups. The adverse event of ocular hypertension was reported narratively and not detected in either group in one study where it was reported. Topical corticosteroids (with or without antibiotics) versus antibiotics The evidence for topical corticosteroids was inconclusive. One study found that topical corticosteroid with antibiotic treatment may reduce symptom scores more than antibiotics alone (MD ‐11.34, 95% CI ‐13.13 to ‐9.55; 1 study, 148 participants), whereas the other found that it may have little to no effect (MD 0.40, 95% CI ‐0.11 to 0.91; 1 study, 201 participants); both, low‐certainty evidence. Topical corticosteroids plus antibiotics probably result in greater reduction in corneal staining scores compared with antibiotics alone (MD ‐1.26, 95% CI ‐1.56 to ‐0.96; 1 study, 148 participants; moderate‐certainty evidence). However, this effect was not observed for tear breakup time when antibiotics alone are likely to perform better (MD ‐1.10, 95% CI ‐1.39 to ‐0.81; 1 study, 148 participants; moderate‐certainty evidence). The adverse event of irritation of the ocular surface was reported narratively, and was similar between the two groups. The adverse event of ocular hypertension was reported narratively, and was higher in the corticosteroid (with or without antibiotics) group. Topical cyclosporine versus placebo Topical cyclosporine may have little to no effect on the composite symptom score compared with placebo, but the evidence is very uncertain (SMD 0.15, 95% CI ‐0.27 to 0.57; 2 studies, 90 participants; very low‐certainty evidence). The evidence is very uncertain about the effect of topical cyclosporine on tear breakup time compared with placebo (invasive time: MD 4.70, 95% CI ‐0.24 to 9.64; 1 study, 26 participants, although for non‐invasive time, it may provide a potential benefit: MD 1.59, 95% CI 1.48 to 1.70; 1 study, 64 participants; both very low‐certainty evidence). Topical cyclosporine...Keywords
This publication has 49 references indexed in Scilit:
- Blepharitis Preferred Practice Pattern®Ophthalmology, 2024
- Topical immunosuppressants for blepharitis in adultsCochrane Database of Systematic Reviews, 2020
- Occurrence of Demodex species in patients with blepharitis and in healthy individuals: a 10-year observational studyJapanese Journal of Ophthalmology, 2018
- Meibomian Glands and Ocular Surface InflammationThe Ocular Surface, 2015
- Dry Eye Disease: Impact on Quality of Life and VisionCurrent Ophthalmology Reports, 2013
- Interventions for chronic blepharitisCochrane Database of Systematic Reviews, 2012
- Blepharitis in the United States 2009: A Survey-based Perspective on Prevalence and TreatmentThe Ocular Surface, 2009
- Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitisAnnals of Allergy, Asthma & Immunology, 2002
- Mechanisms of action of cyclosporineImmunopharmacology, 2000
- Evaluation of a Lens Opacities Classification SystemArchives of Ophthalmology (1950), 1988